Contribution of serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death

Table 2 Logistic regression analysis of baseline systolic dysfunction

Variables	OR (95% CI)	P value
Model 1 (univariate)
Higher FGF21	3.483 (1.182–10.262)	0.024
Higher NT-pro-BNP	9.828 (2.189–44.113)	0.003
Gender	1.043 (0.370–2.942)	0.936
Age	0.966 (0.919–1.015)	0.169
Smoking	1.387 (0.514–3.742)	0.518
History of CVD	0.387 (1.122–1.229)	0.107
Diabetes	0.036 (0.379–2.836)	0.944
Hypertension	1.464 (0.404–5.310)	0.562
Dyslipidemia	1.867 (0.235–14.796)	0.555
NAFLD	1.955 (0.708–5.397)	0.196
Model 2 (multivariate including both higher FGF21 and higher NT-pro-BNP)
Higher FGF21	3.138 (1.037–9.500)	0.043
Higher NT-pro-BNP	9.207 (2.036–41.643)	0.004

Variables adjusted in model 2: gender, age, smoking, history of CVD, diabetes, hypertension, dyslipidemia, and NAFLD
CVD cardiovascular diseases, FGF21 fibroblast growth factor 21, NT-pro-BNP N-terminal pro-brain natriuretic peptide, NAFLD non-alcoholic fatty liver disease

ISSN: 1475-2840